Metabolic acidosis during the relapse treatment of idiopathic intracranial hypertension İdiyopatik intrakraniyal hipertansiyon relaps tedavisi sırasında metabolik asidoz
Agri, cilt.35, sa.2, ss.107-110, 2023 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 35 Sayı: 2
- Basım Tarihi: 2023
- Doi Numarası: 10.14744/agri.2021.05025
- Dergi Adı: Agri
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.107-110
- Anahtar Kelimeler: Acetazolamide, intracranial hypertension, metabolic acidosis, papilledema, SARS-CoV-2 pandemic
- İstanbul Üniversitesi Adresli: Evet
Özet
We herein present a 40-year-old female physician who was diagnosed with idiopathic intracranial hypertension (IIH) 4 years ago. In the last years, the patient was in remission without any medications. Since the onset of COVID-19 pandemic, she has been stressfully working in the high-risk area, therefore using personal protective equipment (N95 mask, protective clothing, goggles, and protective cap) during the day for extended periods. Her headaches recurred and the patient was diagnosed with a relapse of IIH; acetazolamide and afterward topiramate were initiated, with diet treatment. Symptomatic metabolic acidosis, which is otherwise a rare side effect of the IIH treatment and not seen in her first attack even with higher doses, developed during the follow-up, presenting with shortness of breath and chest tightening. The emerging problems of IIH diagnosis and management during the COVID-19 pandemic will be discussed.